Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mafalda Oliveira

Showing results (31-40 of 111) with videos related to

Pageof 12
Sort By:
Therapeutic Advances in Medical Oncology|April 29, 2025
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancerPeter Schmid, Mafalda Oliveira, Joyce O'Shaughnessy, et al.
Breast Cancer Research and Treatment|July 15, 2021
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancerRebecca Dent, Mafalda Oliveira, Steven J Isakoff, et al.
The Lancet. Oncology|February 28, 2017
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trialAntonio Llombart-Cussac, Javier Cortés, Laia Paré, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2026
Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trialChiara Dauccia, Maria Alice Franzoi, Cristina Saura, et al.
Breast Cancer Research and Treatment|December 3, 2021
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trialNicholas Turner, Rebecca A Dent, Joyce O'Shaughnessy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2024
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III TrialRebecca A Dent, Sung-Bae Kim, Mafalda Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>-</sup> Advanced Breast CancerAditya Bardia, Shanu Modi, Mafalda Oliveira, et al.
The Lancet. Oncology|August 13, 2017
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialSung-Bae Kim, Rebecca Dent, Seock-Ah Im, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumorsCinta Hierro, Mònica Sánchez-Guixé, Gabi Tarcic, et al.
The New England Journal of Medicine|October 22, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast CancerJavier Cortés, Kevin Punie, Carlos Barrios, et al.
Pageof 12

Showing results (31-40 of 111) with videos related to

Sort By:
Pageof 12
Therapeutic Advances in Medical Oncology|April 29, 2025
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancerPeter Schmid, Mafalda Oliveira, Joyce O'Shaughnessy, et al.
Breast Cancer Research and Treatment|July 15, 2021
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancerRebecca Dent, Mafalda Oliveira, Steven J Isakoff, et al.
The Lancet. Oncology|February 28, 2017
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trialAntonio Llombart-Cussac, Javier Cortés, Laia Paré, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2026
Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trialChiara Dauccia, Maria Alice Franzoi, Cristina Saura, et al.
Breast Cancer Research and Treatment|December 3, 2021
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trialNicholas Turner, Rebecca A Dent, Joyce O'Shaughnessy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2024
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III TrialRebecca A Dent, Sung-Bae Kim, Mafalda Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>-</sup> Advanced Breast CancerAditya Bardia, Shanu Modi, Mafalda Oliveira, et al.
The Lancet. Oncology|August 13, 2017
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialSung-Bae Kim, Rebecca Dent, Seock-Ah Im, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumorsCinta Hierro, Mònica Sánchez-Guixé, Gabi Tarcic, et al.
The New England Journal of Medicine|October 22, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast CancerJavier Cortés, Kevin Punie, Carlos Barrios, et al.
Pageof 12